元示科技

AI models that predict drug assets' clinical success rates and explain failure risks from limited data such as drug structure, target and indication, giving pharma companies and investors standardized "drug ratings" before capital commitment

Genomic foundation model (diffusion transformer dnaSORA) that locates disease-causing DNA sequences in rare genetic diseases, for pharma and biotech drug discovery

Develops large-scale single-cell datasets to train AI models of human cells for drug discovery

Undisclosed · $30M · 2025-08

Computational medicine and life world models using AI and high-performance computing to simulate disease mechanisms and drug efficacy, systematically discover new oncology targets, assess indications and predict responding patients for novel drug R&D

Series A2 · 2026-08

AI-native drug discovery: proprietary drug foundation models and AI agent engine for early discovery of novel small-molecule, peptide and other drugs

Angel · 2026-09

AI virtual cell models for predicting drug efficacy in humans

Seed · 2026-07

In-house automated wet lab generating large-scale single-cell perturbation data to train "AI virtual cell" models that predict human cell responses to drugs and genetic changes

Seed · 2026-10

AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies

Series B · $2.7B · 2026-05

Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies

Series C · $200M · 2026-09

Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design

Seed · $14M · 2026-08

Develops AI models for drug discovery

AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty